About Biogen (NASDAQ:BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.47%
Current Ratio2.34%
Quick Ratio2.07%
Price-To-Earnings
Trailing P/E Ratio12.29
Forward P/E Ratio10.74
P/E Growth1.48
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales4.59
Cash Flow$26.8707 per share
Price / Cash9.90
Book Value$59.56 per share
Price / Book4.47
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins20.69%
Return on Equity38.32%
Return on Assets20.72%
Miscellaneous
Employees7,300
Outstanding Shares211,560,000
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen (NASDAQ:BIIB) announced its quarterly earnings data on Thursday, January, 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.44 by $0.18. The biotechnology company had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. The company's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.04 earnings per share. View Biogen's Earnings History.
When is Biogen's next earnings date?
What guidance has Biogen issued on next quarter's earnings?
Biogen issued an update on its FY18 earnings guidance on Thursday, January, 25th. The company provided EPS guidance of $24.20-25.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $24.13. The company issued revenue guidance of $12.7-13.0 billion, compared to the consensus revenue estimate of $12.68 billion.
What price target have analysts set for BIIB?
29 analysts have issued 12-month price objectives for Biogen's stock. Their predictions range from $279.00 to $433.00. On average, they expect Biogen's share price to reach $367.2222 in the next year. View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
- 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
- 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
- 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Gilead Sciences (GILD), Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), AveXis (AVXS), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT) and Repligen (RGEN).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
- Mr. Jeffrey D. Capello, Exec. VP of Fin. & CFO (Age 53)
- Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
- Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 54)
Has Biogen been receiving favorable news coverage?
Press coverage about BIIB stock has been trending somewhat positive on Friday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biogen earned a news sentiment score of 0.22 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Biogen's major shareholders?
Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include
PRIMECAP MANAGEMENT COMPANY
(7.16%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $266.02.
How big of a company is Biogen?
Biogen has a market capitalization of $56.71 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biogen (NASDAQ:BIIB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $367.2222, suggesting that the stock has a possible upside of 38.04%. The high price target for BIIB is $433.00 and the low price target for BIIB is $279.00. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.69 | 2.72 | 2.76 | 2.65 |
| Ratings Breakdown: | 0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
20 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
10 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $367.2222 | $370.9259 | $354.00 | $340.4167 |
| Price Target Upside: | 38.04% upside | 32.52% upside | 2.78% upside | 1.18% downside |
Biogen (NASDAQ:BIIB) Consensus Price Target History
Biogen (NASDAQ:BIIB) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Biogen (NASDAQ:BIIB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.92%
Biogen (NASDAQ BIIB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/27/2018 | Alfred Sandrock | EVP | Sell | 259 | $290.83 | $75,324.97 | 6,553 |  |
| 2/20/2018 | Alfred Sandrock | EVP | Sell | 743 | $292.00 | $216,956.00 | 6,553 | |
| 2/15/2018 | Alfred Sandrock | EVP | Sell | 1,294 | $298.85 | $386,711.90 | 7,296 | |
| 1/9/2018 | Robert W Pangia | Director | Sell | 5,832 | $329.65 | $1,922,518.80 | 23,539 | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | 4,879 | |
| 11/29/2017 | Alexander J Denner | Director | Buy | 30,000 | $317.36 | $9,520,800.00 | 10,029 | |
| 7/25/2017 | Susan H Alexander | EVP | Sell | 4,974 | $290.01 | $1,442,509.74 | 22,258 | |
| 7/19/2017 | Susan H Alexander | EVP | Sell | 7,758 | $285.00 | $2,211,030.00 | 27,232 | |
| 6/9/2017 | Brian S Posner | Director | Sell | 1,084 | $256.31 | $277,840.04 | 6,330 | |
| 5/1/2017 | Michel Vounatsos | CEO | Buy | 1,402 | $271.35 | $380,432.70 | | |
| 4/27/2017 | Alexander J. Denner | Director | Buy | 73,858 | $278.50 | $20,569,453.00 | | |
| 4/25/2017 | Paul J Clancy | VP | Sell | 9,892 | $290.00 | $2,868,680.00 | 10,813 | |
| 4/3/2017 | Alfred Sandrock | CMO | Sell | 1,981 | $274.08 | $542,952.48 | 7,060 | |
| 3/13/2017 | Paul J Clancy | VP | Sell | 9,891 | $291.55 | $2,883,721.05 | 20,705 | |
| 2/27/2017 | Michel Vounatsos | CEO | Buy | 1,333 | $285.39 | $380,424.87 | | |
| 1/9/2017 | Robert W Pangia | Director | Sell | 5,450 | $295.39 | $1,609,875.50 | 22,078 | |
| 10/4/2016 | Adriana Karaboutis | EVP | Sell | 262 | $311.94 | $81,728.28 | 7,579 | |
| 10/3/2016 | Adriana Karaboutis | EVP | Sell | 380 | $313.00 | $118,940.00 | 7,172 | |
| 9/22/2016 | Caroline Dorsa | Director | Sell | 27,570 | $314.00 | $8,656,980.00 | 19,663 | |
| 7/21/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 54,779 | |
| 6/6/2016 | Adam Koppel | EVP | Sell | 555 | $290.00 | $160,950.00 | 2,402 | |
| 6/3/2016 | George A Scangos | CEO | Sell | 842 | $290.00 | $244,180.00 | 54,936 | |
| 6/1/2016 | George A Scangos | CEO | Sell | 3,855 | $289.74 | $1,116,947.70 | 56,265 | |
| 5/25/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 59,633 | |
| 5/2/2016 | George A Scangos | CEO | Sell | 487 | $274.74 | $133,798.38 | 59,790 | |
| 4/6/2016 | Adam Koppel | EVP | Sell | 102 | $275.00 | $28,050.00 | 1,848 | |
| 4/6/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 60,277 | |
| 4/1/2016 | George A Scangos | CEO | Sell | 487 | $258.83 | $126,050.21 | 60,434 | |
| 3/1/2016 | George A Scangos | CEO | Sell | 487 | $261.37 | $127,287.19 | 60,921 | |
| 2/25/2016 | Adriana Karaboutis | EVP | Sell | 84 | $261.90 | $21,999.60 | 8,127 | |
| 2/25/2016 | Alfred Sandrock | CMO | Sell | 183 | $261.90 | $47,927.70 | 7,990 | |
| 2/17/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 722 | $256.16 | $184,947.52 | 7,990 | |
| 2/17/2016 | George A Scangos | CEO | Sell | 487 | $256.16 | $124,749.92 | 59,848 | |
| 2/9/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 852 | $246.54 | $210,052.08 | 7,740 | |
| 12/4/2015 | Alfred Sandrock | CMO | Sell | 441 | $277.00 | $122,157.00 | 7,740 | |
| 10/23/2015 | Alexander J Denner | Director | Buy | 310,000 | $277.47 | $86,015,700.00 | 7,890 | |
| 7/27/2015 | Stelios Papadopoulos | Director | Buy | 10,000 | $304.88 | $3,048,800.00 | | |
| 6/19/2015 | Douglas E Williams | EVP | Sell | 3,841 | $410.00 | $1,574,810.00 | | |
| 6/1/2015 | George A Scangos | CEO | Sell | 1,362 | $398.87 | $543,260.94 | | |
| 4/1/2015 | George A Scangos | CEO | Sell | 1,362 | $423.20 | $576,398.40 | | |
| 3/25/2015 | John Cox | EVP | Sell | 12,010 | $449.06 | $5,393,210.60 | | |
| 3/20/2015 | Eric K Rowinsky | Director | Sell | 11,667 | $475.00 | $5,541,825.00 | | |
| 3/19/2015 | Eric K Rowinsky | Director | Sell | 2,333 | $436.14 | $1,017,514.62 | | |
| 3/17/2015 | Eric K Rowinsky | Director | Sell | 4,667 | $425.45 | $1,985,575.15 | | |
| 3/10/2015 | Robert W Pangia | Director | Sell | 3,625 | $413.40 | $1,498,575.00 | | |
| 3/2/2015 | Alfred Sandrock | SVP | Sell | 3,174 | $409.49 | $1,299,721.26 | | |
| 2/17/2015 | Steven H Holtzman | EVP | Sell | 2,128 | $389.11 | $828,026.08 | | |
| 2/10/2015 | Alfred Sandrock | SVP | Sell | 1,143 | $398.11 | $455,039.73 | | |
| 2/2/2015 | Kenneth Dipietro | EVP | Sell | 1,656 | $389.03 | $644,233.68 | | |
| 12/15/2014 | Spyridon Artavanis-Tsakonas | SVP | Sell | 1,981 | $346.50 | $686,416.50 | | |
| 12/2/2014 | Steven H Holtzman | EVP | Sell | 1,749 | $335.65 | $587,051.85 | | |
| 11/11/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.00 | $577,500.00 | | |
| 11/3/2014 | George A Scangos | CEO | Sell | 1,128 | $320.78 | $361,839.84 | | |
| 10/1/2014 | George A Scangos | CEO | Sell | 1,127 | $330.97 | $373,003.19 | | |
| 10/1/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.97 | $579,197.50 | | |
| 8/1/2014 | George A Scangos | CEO | Sell | 1,128 | $332.93 | $375,545.04 | | |
| 7/16/2014 | George A Scangos | CEO | Sell | 12,316 | $312.37 | $3,847,148.92 | | |
| 5/19/2014 | Steven Holtzman | EVP | Sell | 1,221 | $289.15 | $353,052.15 | 5,749 | |
| 5/1/2014 | George Scangos | CEO | Sell | 2,123 | $285.56 | $606,243.88 | 24,019 | |
| 4/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $291.00 | $355,311.00 | 6,970 | |
| 4/1/2014 | George Scangos | CEO | Sell | 2,123 | $308.42 | $654,775.66 | 26,142 | |
| 4/1/2014 | Robert Pangia | Director | Sell | 6,250 | $308.42 | $1,927,625.00 | 14,003 | |
| 3/31/2014 | Brian Posner | Director | Sell | 3,000 | $296.76 | $890,280.00 | 6,435 | |
| 3/20/2014 | Caroline Dorsa | Director | Sell | 10,000 | $348.88 | $3,488,800.00 | 14,468 | |
| 3/19/2014 | Douglas Williams | EVP | Sell | 3,505 | $352.29 | $1,234,776.45 | 7,976 | |
| 3/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $334.83 | $408,827.43 | 8,191 | |
| 3/11/2014 | Stuart Kingsley | EVP | Sell | 8,428 | $336.83 | $2,838,803.24 | 3,511 | |
| 3/3/2014 | George Scangos | CEO | Sell | 2,942 | $335.79 | $987,894.18 | 54,389 | |
| 2/26/2014 | Alfred Sandrock | SVP | Sell | 1,048 | $342.17 | $358,594.16 | 21,407 | |
| 2/18/2014 | Steven Holtzman | EVP | Sell | 1,222 | $327.90 | $400,693.80 | 9,412 | |
| 2/13/2014 | Kenneth Dipietro | EVP | Sell | 1,290 | $316.81 | $408,684.90 | | |
| 2/11/2014 | Alfred Sandrock | SVP | Sell | 2,085 | $314.31 | $655,336.35 | 13,667 | |
| 2/11/2014 | George Scangos | CEO | Sell | 2,456 | $314.31 | $771,945.36 | 52,961 | |
| 2/4/2014 | Kenneth Dipietro | EVP | Sell | 1,655 | $299.01 | $494,861.55 | | |
| 1/21/2014 | Eric Rowinsky | Director | Sell | 2,020 | $310.09 | $626,381.80 | 10,440 | |
| 1/15/2014 | Lynn Schenk | Director | Sell | 1,000 | $297.48 | $297,480.00 | 3,325 | |
| 1/8/2014 | William Young | Director | Sell | 15,000 | $285.11 | $4,276,650.00 | 18,509 | |
| 1/6/2014 | Robert Pangia | Director | Sell | 6,250 | $278.03 | $1,737,687.50 | 14,003 | |
| 12/2/2013 | Lynn Schenk | Director | Sell | 1,000 | $291.71 | $291,710.00 | 3,325 | |
| 11/22/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $288.00 | $1,152,000.00 | 8,710 | |
| 11/1/2013 | George A Scangos | CEO | Sell | 2,239 | $245.57 | $549,831.23 | | |
| 11/1/2013 | Lynn Schenk | Director | Sell | 1,000 | $245.00 | $245,000.00 | | |
| 10/22/2013 | Alfred Sandrock | SVP | Sell | 15,030 | $250.11 | $3,759,153.30 | | |
| 9/18/2013 | Paul Clancy | CFO | Sell | 26,785 | $245.00 | $6,562,325.00 | 7,087 | |
| 9/17/2013 | Steven Holtzman | EVP | Sell | 3,501 | $238.98 | $836,668.98 | 4,885 | |
| 9/16/2013 | Paul Clancy | CFO | Sell | 99,030 | $238.27 | $23,595,878.10 | 7,087 | |
| 9/16/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $238.03 | $952,120.00 | 8,710 | |
| 9/3/2013 | George Scangos | CEO | Sell | 2,239 | $214.40 | $480,041.60 | 43,522 | |
| 8/26/2013 | Douglas Williams | EVP | Sell | 4,368 | $211.35 | $923,176.80 | 4,571 | |
| 8/1/2013 | George A Scangos | CEO | Sell | 2,239 | $218.82 | $489,937.98 | | |
| 7/16/2013 | George A Scangos | CEO | Sell | 2,239 | $223.94 | $501,401.66 | | |
| 6/14/2013 | Alexander J Denner | Director | Sell | 2,900 | $212.00 | $614,800.00 | | |
| 6/11/2013 | Brian S Posner | Director | Sell | 2,020 | $219.62 | $443,632.40 | | |
| 6/10/2013 | Lynn Schenk | Director | Sell | 2,000 | $225.82 | $451,640.00 | | |
| 6/3/2013 | George A Scangos | CEO | Sell | 1,598 | $234.16 | $374,187.68 | | |
| 6/3/2013 | Stephen A Sherwin | Director | Sell | 12,825 | $233.26 | $2,991,559.50 | | |
| 5/28/2013 | Robert W Pangia | Director | Sell | 5,900 | $237.23 | $1,399,657.00 | | |
| 12/27/2012 | Alexander J Denner | Director | Sell | 7,980 | $148.62 | $1,185,987.60 | | |
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biogen (BIIB) Given Hold Rating at Jefferies Group
www.americanbankingnews.com - April 19 at 3:35 PM |
| Q2 2018 Earnings Forecast for Biogen Issued By Leerink Swann (BIIB)
www.americanbankingnews.com - April 19 at 6:44 AM |
| Biogen (BIIB) Upgraded at Vetr
www.americanbankingnews.com - April 19 at 12:28 AM |
 | Biogen (BIIB) Missed Out on AveXis (AVXS) But Well-Positioned for Substantial Acquisition - RBC
www.streetinsider.com - April 18 at 5:47 PM |
| Biogen (BIIB) Given a $384.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - April 18 at 8:40 AM |
| Q1 2018 Earnings Estimate for Biogen (BIIB) Issued By Leerink Swann
www.americanbankingnews.com - April 18 at 7:58 AM |
| Biogen (BIIB) Given Hold Rating at BMO Capital Markets
www.americanbankingnews.com - April 17 at 8:07 PM |
 | Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and ...
www.businesswire.com - April 17 at 8:27 AM |
 | Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
finance.yahoo.com - April 17 at 8:26 AM |
| Biogen (BIIB) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - April 17 at 1:41 AM |
| How Did Biogen Miss AveXis?
finance.yahoo.com - April 16 at 5:27 PM |
 | Factors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan ...
globenewswire.com - April 16 at 8:13 AM |
| Factors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan, Community Health, Enphase Energy, and Exxon Mobil — New Research Emphasizes Economic Growth
finance.yahoo.com - April 16 at 8:13 AM |
| Biogen to Post Q1 2018 Earnings of $6.00 Per Share, Piper Jaffray Forecasts (BIIB)
www.americanbankingnews.com - April 16 at 1:44 AM |
| Biogen (BIIB) Upgraded by Goldman Sachs to Buy
www.americanbankingnews.com - April 15 at 9:29 PM |
| Biogen (BIIB) Downgraded to "Hold" at Vetr
www.americanbankingnews.com - April 15 at 8:22 PM |
| Biogen's (BIIB) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - April 15 at 7:48 PM |
| Biogen (BIIB) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 1:40 PM |
 | Why One Drug Flop Tanked Incyte's Stock
www.fool.com - April 13 at 8:17 AM |
| Biogen’s Key Drug for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - April 12 at 5:40 PM |
 | Biogen up 1% on potential sale of part of Bioepis stake to Samsung Group
seekingalpha.com - April 12 at 8:32 AM |
| The Zacks Analyst Blog Highlights: NextEra, Danaher, Biogen, Facebook and Apple
finance.yahoo.com - April 12 at 8:32 AM |
| What Analysts Recommend for Incyte in April 2018
finance.yahoo.com - April 11 at 5:34 PM |
| Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen
finance.yahoo.com - April 11 at 5:34 PM |
| Mizuho Reiterates $433.00 Price Target for Biogen (BIIB)
www.americanbankingnews.com - April 11 at 2:21 PM |
| 10 Cheap, High-Quality Stocks With Major Growth Catalysts
finance.yahoo.com - April 11 at 8:26 AM |
| Sanford C. Bernstein Analysts Give Biogen (BIIB) a $318.00 Price Target
www.americanbankingnews.com - April 10 at 9:16 AM |
| Zacks: Analysts Expect Biogen Inc (BIIB) Will Announce Quarterly Sales of $3.15 Billion
www.americanbankingnews.com - April 10 at 2:38 AM |
| Biogen (BIIB) Cut to "Buy" at Vetr
www.americanbankingnews.com - April 9 at 10:55 PM |
| Vetr Lowers Biogen (BIIB) to Buy
www.americanbankingnews.com - April 9 at 8:36 PM |
| Biogen (BIIB) PT Set at $350.00 by Canaccord Genuity
www.americanbankingnews.com - April 9 at 6:25 PM |
| Novartis (NVS) Acquisition of AveXis (AVXS) is Incremental Negative for Biogen (BIIB) - UBS
www.streetinsider.com - April 9 at 8:16 AM |
| Biogen Inc (BIIB) to Post Q1 2018 Earnings of $5.85 Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - April 9 at 1:39 AM |
| Jefferies Group Equities Analysts Boost Earnings Estimates for Biogen Inc (BIIB)
www.americanbankingnews.com - April 9 at 1:39 AM |
| Zacks: Brokerages Expect Biogen Inc (BIIB) Will Announce Earnings of $5.95 Per Share
www.americanbankingnews.com - April 8 at 5:20 PM |
| Biogen (BIIB) Lifted to "Buy" at Mizuho
www.americanbankingnews.com - April 6 at 11:33 PM |
| Stifel Nicolaus Upgrades Biogen (BIIB) to "Buy"
www.americanbankingnews.com - April 6 at 11:32 PM |
| Citigroup Lowers Biogen (BIIB) to Neutral
www.americanbankingnews.com - April 6 at 11:11 AM |
| Biogen (BIIB) & Samsung Bioepis Report Settlement with AbbVie (ABBV) for Commercialization of IMRALDI ...
www.streetinsider.com - April 5 at 5:19 PM |
| BMO Capital Markets Upgrades Biogen (BIIB) to Outperform
www.americanbankingnews.com - April 5 at 3:30 PM |
| UBS Boosts Biogen (BIIB) Price Target to $318.00
www.americanbankingnews.com - April 5 at 2:58 PM |
| Biogen (BIIB) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - April 5 at 2:17 PM |
| Biogen (BIIB) Lowered to Equal Weight at Barclays
www.americanbankingnews.com - April 5 at 11:32 AM |
| Barclays Downgrades Biogen (BIIB) to Equalweight
www.streetinsider.com - April 5 at 10:07 AM |
| Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI ...
www.businesswire.com - April 5 at 10:07 AM |
| Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
finance.yahoo.com - April 5 at 10:07 AM |
| AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023
finance.yahoo.com - April 5 at 10:07 AM |
| Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier
finance.yahoo.com - April 4 at 4:15 PM |
| Analysts’ Recommendations for BioMarin Pharmaceutical
finance.yahoo.com - April 4 at 8:18 AM |
 | Biogen CEO scoops up $2.3M Back Bay condo
www.bizjournals.com - April 3 at 5:37 PM |
Biogen (NASDAQ:BIIB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement
Biogen (NASDAQ BIIB) Stock Chart for Friday, April, 20, 2018
Loading chart…
